Cost Plus Drug Company vs CoverMyMeds
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mark Cuban Cost Plus Drug Company offers generic prescription medications at transparent cost-plus pricing; has expanded to over 2,500 generic drugs priced at cost plus 15% markup; partners with pharmacies nationwide;
About
Mark Cuban Cost Plus Drug Company (also known as Cost Plus Drugs) is a direct-to-consumer pharmaceutical company co-founded in 2022 by Mark Cuban and Alex Oshmyansky and headquartered in Dallas, Texas. The company disrupts the opaque and often inflated pricing of generic pharmaceuticals by operating on a transparent cost-plus model: it sources generic drugs directly from manufacturers, adds a fixed 15% markup, a $3 pharmacy labor fee, and a $5 shipping fee — publishing the final price for every drug openly on its website. This approach bypasses the traditional pharmacy benefit manager (PBM) system, which critics argue inflates drug prices through rebate structures that benefit intermediaries at the expense of patients and payers.
Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies;
About
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.